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Introduction {#cam4738-sec-0001}
============

Although the incidence of colorectal cancer (CRC) in both men and women is decreasing [1](#cam4738-bib-0001){ref-type="ref"}, CRC remains the third most common cancer and the third leading cause of cancer death in men and women in the United States [2](#cam4738-bib-0002){ref-type="ref"}. The survival of patients with CRC is closely related to the occurrence of metastasis, especially to the liver [3](#cam4738-bib-0003){ref-type="ref"}, [4](#cam4738-bib-0004){ref-type="ref"}. Indeed, hepatic metastases are observed in 75--83% of all metastatic CRC [5](#cam4738-bib-0005){ref-type="ref"}, [6](#cam4738-bib-0006){ref-type="ref"}, [7](#cam4738-bib-0007){ref-type="ref"}. Lack of specificity and sensitivity precludes the application of all existing serum markers, such as carcinoembryonic antigen (CEA), for the early detection of CRC [4](#cam4738-bib-0004){ref-type="ref"}, [8](#cam4738-bib-0008){ref-type="ref"}. Diagnosis of CRC patients with liver metastases still depend on radiology and biopsy [4](#cam4738-bib-0004){ref-type="ref"}. Nevertheless, it is well known that the radiology guided biopsy also has its limitation of sensitivity. Therefore, in order to improve the survival of CRC patients, exploring new biomarkers and the molecular mechanisms underlying metastatic progression in CRC is expected that may lead to the earlier diagnosis and treatment of patients with liver metastases.

Recent studies have revealed that noncoding RNAs (ncRNAs), including ribosomal RNA (rRNA), transfer RNA (tRNA), microRNA (miRNA), and long noncoding RNA (lncRNA), participate in many biological and pathological processes [9](#cam4738-bib-0009){ref-type="ref"}, [10](#cam4738-bib-0010){ref-type="ref"}. In contrast to small ncRNAs, lncRNAs contain 200--100,000 nucleotides in length. Although the recent application of next‐generation sequencing to a growing number of cancer transcriptomes has indeed revealed thousands of lncRNAs whose aberrant expression is associated with different cancer types, few of which have been functionally characterized [11](#cam4738-bib-0011){ref-type="ref"}. lncRNAs have key roles in gene regulation and thus affect various aspects of cellular homeostasis, including proliferation, survival, migration, or genomic stability [11](#cam4738-bib-0011){ref-type="ref"}. Moreover, there is increasing evidence that many lncRNAs play significant roles in the regulation of CRC [12](#cam4738-bib-0012){ref-type="ref"}.

Among these lncRNAs, the up‐regulation of HOTAIR, MALAT1, CCAT2, and the down‐regulation of LOC285194, UC.388, and LET have been implicated in promoting metastasis of CRC [12](#cam4738-bib-0012){ref-type="ref"}. However, the biological and pathological functions of most lncRNAs are still unclear. In this study, we examined differentially expressed lncRNAs and mRNAs in tissues obtained from CRC patients with (experimental group, Exp G) and without (control group, Ctrl G) liver metastasis, aiming to identify novel diagnostic and prognostic markers in CRC patients with liver metastasis.

Materials and Methods {#cam4738-sec-0002}
=====================

Samples {#cam4738-sec-0003}
=======

Samples were collected from patients in the Department of Colorectal Surgery, First Affiliated Hospital, Zhejiang University, between October 2014 and May 2015. Twelve primary CRC samples were obtained from six patients with CRC and liver metastasis (Exp G) and six patients with CRC without metastasis (Ctrl G) (Table [1](#cam4738-tbl-0001){ref-type="table-wrap"}). None of the patients had received neoadjuvant therapy, and the samples were pathologically confirmed postoperatively as colorectal adenocarcinoma. The samples were taken within 10 min after tumor excision, immediately immersed in RNA later^®^ stabilization solution (Thermo Fisher Scientific, Carlsbad, CA, USA), and then stored at −80°C until used in the experiments. Written informed consents were obtained from all patients and this study was approved by the Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University.

###### 

List of the clinical information

  No.     Age (yrs)   Gender   Primary location   Metastasis   Disease duration   Pathology grade[a](#cam4738-note-0004){ref-type="fn"}   Tumor size (cm)   Clinical stages[b](#cam4738-note-0005){ref-type="fn"}   Operation method[c](#cam4738-note-0006){ref-type="fn"}
  ------- ----------- -------- ------------------ ------------ ------------------ ------------------------------------------------------- ----------------- ------------------------------------------------------- --------------------------------------------------------
  Exp1    52          F        Descending colon   Liver        1 month            PDA                                                     7.5 × 3.5         T4N2M1                                                  LPH + LLH
  Exp2    72          M        Descending colon   Liver        15 days            MA                                                      6.0 × 3.0         T4N1M1                                                  LLH + BLM
  Exp3    62          M        Rectum             Liver        4 months           MA                                                      3.5 × 2.5         T3N1M1                                                  LAR + LPH
  Exp4    68          M        Rectum             Liver        2 month            PDA                                                     2.5 × 2.0         T3N2M1                                                  AR + PH
  Exp5    64          M        Ascending colon    Liver        8 month            PDA                                                     4.0 × 4.01        T4N2M                                                   RH[d](#cam4738-note-0007){ref-type="fn"}
  Exp6    66          F        Sigmoid colon      Liver        10 day             MA                                                      4.0 × 3.5         T4N2M1                                                  R SCC[d](#cam4738-note-0007){ref-type="fn"}
  Ctrl1   81          M        Descending colon   No           4 month            MA                                                      5.0 × 4.0         T3N2M0                                                  LLH
  Ctrl2   50          M        Ascending colon    No           5 month            PDA                                                     3.0 × 3.00        T3N1M                                                   RH
  Ctrl3   56          M        Ascending colon    No           2 month            MA                                                      8.0 × 4.5         T4N0M0                                                  RH
  Ctrl4   64          M        Descending colon   No           2 month            MDA                                                     6.0 × 5.5         T3N0M0                                                  LLH
  Ctrl5   84          M        Ascending colon    No           3 month            MA                                                      3.0 × 3.0         T2N0M0                                                  LRH
  Ctrl6   78          F        Ascending colon    No           12 month           MA                                                      12.0 × 12.0       T3N0M0                                                  RH

Exp G, Experimental group; Ctrl G, Control group.

MA, Mucinous adenocarcinoma; MDA, Moderately differentiated adenocarcinoma; PDA, Poorly differentiated adenocarcinoma.

It includes lymphatic metastasis as N stage.

AR, Anterior resection; BLM, Biopsy of liver metastases; LAR, Laparoscopic anterior resection; LLH, Laparoscopic left hemicolectomy; LPH, Laparoscopic partial hepatectomy; LRH, Laparoscopic right hemicolectomy; PH, Partial hepatectomy; RH, Right hemicolectomy; RSCC, Resection of sigmoid colon cancer.

The liver metastasis had been confirmed by preoperative liver biopsy.
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RNA isolation and quality control {#cam4738-sec-0004}
=================================

Total cellular RNA was isolated from each sample using a homogenizer (IKA, Germany) and TRI zol reagent (Invitrogen, Carlsbad, CA) and then purified using the RNeasy mini kit (Qiagen, Hilden, Germany) according to the manufacturer\'s protocol. The purified RNA was quantitated using the Nano Drop ND‐1000 spectrophotometer (Thermo Fisher Scientific) and its quality was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).

Microarray analysis {#cam4738-sec-0005}
===================

Human 8 × 60K lncRNA/mRNA v3.0 microarrays (Arra‐ystar, Rockville, MD, USA) designed for the global profiling of 30,586 human lncRNAs and 26,109 protein‐coding transcripts from validated public transcriptomic databases (Refseq, UCSC known genes, Gencode, and others) and landmark publications, were used in our study. Each transcript was confirmed using 1--5 probes to improve statistical confidence. The lncRNA expression data have been deposited in the Gene Expression Omnibus database under the accession number GSE75050.

RNA labeling and array hybridization {#cam4738-sec-0006}
====================================

Sample labeling and array hybridization were performed according to the protocol provided with the Agilent One‐Color microarray‐based gene expression analysis kit (Agilent Technology). Briefly, mRNA was purified from total RNA by the removal of rRNA (mRNA‐ONLY^™^ eukaryotic mRNA isolation kit, Epicentre). Each sample was then amplified and transcribed into fluorescently labeled cRNA corresponding to the entire length of the transcripts, without 3′ bias, utilizing a mixture of oligo (dT) and random primers (Arraystar Flash RNA labeling kit; Arraystar). The labeled cRNAs were purified using the RNeasy mini kit (Qiagen) while their concentration and specific activity (pmol Cy3/*μ*gcRNA) were determined using the Nano Drop ND‐1000. The labeled cRNAs (1 *μ*g each) were fragmented by adding 5 *μ*L 10 × blocking agent and 1 *μ*L 25 × fragmentation buffer, followed by heating the mixture at 60°C for 30 min. The labeled cRNA was diluted with 25 *μ*L 2 × GE hybridization buffer. Fifty microliters of hybridization solution were dispensed into the gasket slide, which was then assembled onto the lncRNA expression microarray slide. The assembly was incubated for 17 h at 65°C in an Agilent bridization oven. The hybridized arrays were then washed, fixed, and scanned using the Agilent DNA microarray scanner (part number G2505C).

Data analysis {#cam4738-sec-0007}
=============

Agilent feature extraction software (version 11.0.1.1) was used to analyze the acquired array images. Quantile normalization and subsequent data processing were performed using the Gene Spring GX v12.1 software package (Agilent Technologies). Quantile‐normalized lncRNAs and mRNAs in which at least six of 12 samples were flagged as present or marginal ("All Targets Value") were chosen for further analysis. *P*‐value/FDR filtering was used to identify the lncRNAs and mRNAs whose expression significantly differed between Exp G and Ctrl G. These differentially expressed lncRNAs and mRNAs were identified through fold change filtering. Hierarchical clustering and combined analyses were performed using in‐house scripts.

Gene function analysis {#cam4738-sec-0008}
======================

The GO project provides a controlled vocabulary to describe the genes and gene products of any organism (<http://www.geneontology.org>). The ontology covers three domains: biological process, cellular component and molecular function. Fisher\'s exact test is used to determine whether the overlap between the differential expression list and the GO annotation list is greater than would be expected by chance. Pathway analysis is a functional analysis that maps genes to Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. The *P*‐value (EASE‐score, Fisher\'s exact test *P*‐value, or hyper geometric *P*‐value) denotes the significance of the GO term and thus the pathway that correlates with the conditions. The lower the *P*‐value, the more significant the pathway and GO term. A *P*‐value ≤ 0.05 is recommended.

Target mRNA selection and construction of the coding‐noncoding gene co‐expression network {#cam4738-sec-0009}
=========================================================================================

Several mRNAs with normalized high‐intensity expression and a high fold change were selected and then verified by quantitative reverse transcription‐polymerase chain reaction (qRT‐PCR), performed in triplicate. Significantly expressed mRNAs were superimposed onto the lncRNA‐mRNA correlation network to determine their association with the lncRNAs. Those that significantly differed were used in the construction of an lncRNA‐mRNA regulatory network.

In the network, the pink node represents significantly expressed mRNAs and the blue node represents the related lncRNA; the red solid line shows direct connections and a positive correlation between a given lncRNA and a mRNA; the green line indicates their direct connections and a negative correlation.

qRT‐PCR for selected lncRNAs {#cam4738-sec-0010}
============================

Total cellular RNAs were isolated from primary CRC tissues of the two groups using TRI zol reagent (Invitrogen) and then reverse transcribed using the Prime Script RT reagent kit together with gDNA Eraser (Perfect Real Time; Ta Ka Ra, Dalian, China) in accordance with the manufacturer\'s instructions. According to the microarray results and the analysis of the lncRNA‐mRNA regulatory network, a significantly down‐regulated mRNA (NM_000904; NQO2, NAD (P) H Dehydrogenase, Quinone 2) and 10 correlative lncRNAs \[five up‐regulated (NR_046711, NR_004855, NR_036537, NR_036580 and NR_002795) and five down‐regulated (NR_034129, NR_033878, NR_036484, NR_027054 and NR_027242)\] were analyzed by qRT‐PCR (quantitative reverse transcription‐polymerase chain reaction) performed in triplicate using a SYBR Green PCR kit (Ta Ka Ra). Glyceraldehyde3‐phosphate dehydrogenase (GAPDH) mRNA was used as an internal control.

Statistical analyses {#cam4738-sec-0011}
====================

SPSS software (version 16.0, Chicago, IL) was used for the statistical analyses. The data were expressed as the mean ± standard deviation. The microarray data variables were compared between the two groups using Student\'s *t*‐test. Microarray results were evaluated based on fold changes, and a ≥ 2.0‐fold increase/decrease in lncRNAs or mRNAs was considered statistically significant (*P *\< 0.05). Expression of the lncRNAs and mRNAs was compared between the two groups using Student\'s *t*‐test; *P *\< 0.05 was considered to indicate statistical significance.

Results {#cam4738-sec-0012}
=======

Differentially expressed lncRNAs and mRNAs in the tissues of CRC patients with liver metastasis {#cam4738-sec-0013}
-----------------------------------------------------------------------------------------------

A genome‐wide analysis was performed to profile difference in lncRNA and mRNA expression between Exp G and Ctrl G (Fig. [1](#cam4738-fig-0001){ref-type="fig"}). The differences were assessed using authoritative data sources. The 2636 significantly dysregulated lncRNAs (fold change ≥2.0, *P *\< 0.05) consisted of 1600 up‐regulated and 1036 down‐regulated lncRNAs (Table S1). In addition, significant differences in the expression of 1584 mRNAs (≥2.0‐fold change, *P *\< 0.05) between the two groups were determined. In Exp G, 548 and 1036 mRNAs were significantly up‐ and down‐regulated (≥2.0‐fold change; *P *\< 0.05; Table S2).

![Differentially expressed long noncoding RNAs (lncRNAs) and mRNAs in colorectal cancer (CRC) tissues from patients with Liver Metastasis (Exp G) and without metastasis (Ctrl G). Hierarchical cluster analysis of CRC samples to assess the significant expression of lncRNAs (A1) and mRNAs (A2) based on microarray analyses. Red denotes high relative expression and green low relative expression. Each RNA is represented by a single row of colored boxes and each sample by a single column. The box plot shows the variations in lncRNA (B1) and mRNA (B2) expression. The scatter plot and the volcano plot illustrate the distributions of the data in the lncRNA (C1, D1) and mRNA (C2, D2) profiles. After data normalization, the distributions of the log~2~ ratios among samples were nearly the same. The values of the x‐ and y‐axes in the scatter plot were the averaged normalized signal values of the group (log~2~ scaled). The green lines in the scatter and volcano plots show the significant fold change.](CAM4-5-1629-g001){#cam4738-fig-0001}

Gene ontology and pathway analyses {#cam4738-sec-0014}
----------------------------------

In the GO analysis, the up‐ and down‐regulated mRNAs were analyzed separately. In the biological process analysis, single‐organism (341, 17.42%), single‐organism cellular (313, 15.99%) and multicellular organismal (210, 10.73%) were the three most significant processes associated with the up‐regulated mRNAs, while cellular (710, 13.45%), single‐organism (680, 12.88%) and single‐organism cellular (628, 11.9%) were the three most significant processes among the down‐regulated mRNAs. In the cellular component analysis, membrane part (176, 14.08%), intrinsic component of membrane (155, 12.40%) and cell periphery (154, 12.32%) were the three most significant component processes associated with the up‐regulated mRNAs, while membrane (450, 14.65%), cytoplasmic part (369, 12.01%) and membrane part (354, 11.52%) were the three most significant component processes associated the down‐regulated mRNAs. In the molecular function analysis, transporter (52, 12.15%), substrate‐specific transporter (44, 10.28%) and substrate‐specific transmembrane transporter (43, 10.05%) activities were the three most significant functions of the up‐regulated mRNAs, whereas binding (626, 34.95%), protein binding (465, 25.96%) and receptor activity (106, 5.92%) were the three most significant functions of the down‐regulated mRNAs. In the GO analysis, the enrichment score and fold enrichment of these up‐regulated and down‐regulated mRNAs also differed (Fig. [2](#cam4738-fig-0002){ref-type="fig"} and Table S3). Pathway analysis identified 27 and 51 gene pathways targeted by the up‐ and down‐regulated mRNAs, respectively (Fig. [3](#cam4738-fig-0003){ref-type="fig"} and Table S4).

![Gene ontology (GO) enrichment analysis of lncRNA‐target genes. GO analysis of lncRNA‐target genes according to biological process (A), cell component (B) and molecular function (C), including analyses of the up‐regulated (A1, B1 and C1) and down‐regulated (A2, B2 and C2) lncRNAs.](CAM4-5-1629-g002){#cam4738-fig-0002}

![The top 10 enrichment scores in the pathway analysis of the up‐regulated (A) and down‐regulated (B) mRNAs. The lower panel shows the leading pathways associated with the up‐regulated (C) and down‐regulated (D) mRNAs.](CAM4-5-1629-g003){#cam4738-fig-0003}

Target mRNAs selection and coding‐noncoding gene co‐expression network construction {#cam4738-sec-0015}
-----------------------------------------------------------------------------------

lncRNAs are involved in the regulation of gene expression at the transcriptional, epigenetic, and posttranscriptional levels. Therefore, in this study, the lncRNAs potentially related to liver metastasis in CRC were expected to be associated with the differentially expressed mRNAs identified. Accordingly, from these differentially expressed mRNAs, 10 mRNAs have high normalized intensities and high fold changes (NM_012330, NM_014389, ENST00000347619, ENST00000312942, NM_002247, NM_006103, NM_000904, NM_015032, NM_001008493, and NM_000577) and they were further verified by qRT‐PCR. However, significant expression was confirmed only for NM_000904 (NQO2) (Table [2](#cam4738-tbl-0002){ref-type="table-wrap"}). Using Pearson\'s correlation coefficient analysis (*P* ≥ 0.95), we identified 769 potentially associated lncRNAs in the database. We then integrated the predicted potential lncRNA targets with the differentially expressed mRNA‐NQO2 (NM_000904) to construct a coding‐noncoding gene co‐expression network (Fig. [4](#cam4738-fig-0004){ref-type="fig"}). Detailed information is presented in Table S5.

###### 

The expression of selected mRNAs in the verification of qRT‐PCR

  Selected mRNA     Exp G               Ctrl G              Fold change[a](#cam4738-note-0009){ref-type="fn"}   *P*‐value
  ----------------- ------------------- ------------------- --------------------------------------------------- ---------------------------------------------
  NM_012330         1.35E‐2 ± 6.06E‐3   1.08E‐2 ± 4.89E‐3   1.25                                                0.416
  NM_014389         4.11E‐4 ± 1.50E‐4   6.10E‐4 ± 2.28E‐4   0.68                                                0.105
  NM_002247         3.85E‐4 ± 2.99E‐4   7.59E‐4 ± 4.60E‐4   0.51                                                0.126
  NM_006103         4.20E‐1 ± 7.56E‐1   2.49E‐2 ± 2.40E‐2   16.67                                               0.259
  NM_000577         1.31E‐2 ± 7.52E‐3   2.79E‐2 ± 2.81E‐2   0.47                                                0.249
  NM_000904         3.62E‐3 ± 1.53E‐3   9.42E‐3 ± 5.48E‐3   0.38                                                0.026[b](#cam4738-note-0010){ref-type="fn"}
  NM_015032         1.84E‐3 ± 9.41E‐4   9.32E‐4 ± 6.92E‐4   1.96                                                0.080
  NM_001008493      1.22E‐2 ± 7.86E‐3   1.46E‐2 ± 6.65E‐3   0.83                                                0.538
  ENST00000312942   3.24E‐3 ± 3.36E‐3   2.15E‐3 ± 2.34E‐3   1.52                                                0.562
  ENST00000347619   1.61E‐3 ± 1.34E‐3   1.61E‐3 ± 7.97E‐4   1.00                                                0.992

Exp G, Experimental group; Ctrl G, Control group;

\>1 means up‐regulated, \<1 means down‐regulated;

*P* \< 0.05, indicates a significant difference between two groups.

John Wiley & Sons, Ltd

![Predictions of the coding‐noncoding gene co‐expression network. The co‐expression network was composed of one mRNA and 769 potentially associated lncRNAs. The 340 direct connections, indicated by the red solid line, are those in which the correlation between the mRNA and the potentially associated lncRNAs was positive. The 429 direct connections, indicated by the green solid line show the respective of negative correlations.](CAM4-5-1629-g004){#cam4738-fig-0004}

qRT‐PCR validation of the co‐expression network genes {#cam4738-sec-0016}
-----------------------------------------------------

Five up‐regulated (NR_046711, NR_004855, NR_036537, NR_036580, and NR_002795) and five down‐regulated (NR_034129, NR_033878, NR_036484, NR_027054, and NR_027242) lncRNAs were selected from the 12 CRC samples for further verification by qRT‐PCR. Four significantly up‐regulated (NR_046711, NR_036537, NR_036580, and NR_002795) and two significantly down‐regulated (NR_033878 and NR_036484) lncRNAs showed the same fold change patterns as those in the microarray results. The fold changes of the other four lncRNAs (NR_034129, NR_004855, NR_027054, and NR_027242) did not reach statistical significance (Fig. [5](#cam4738-fig-0005){ref-type="fig"}).

![Quantitative reverse transcription‐polymerase chain reaction (qRT‐PCR) validation of 10 randomly selected differentially expressed lncRNAs. Six of the qRT‐PCR‐validated lncRNAs (NR_046711, NR_036537, NR_036580, NR_002795, NR_033878, and NR_036484) showed the same fold change tendencies as those in the microarray results (\**P* \< 0.05). The differences in the other four qRT‐PCR‐validated lncRNAs (NR_034129, NR_004855, NR_027054 and NR_027242) were not statistically significant. (A) Comparison of the microarray data and qPCR results; (B) Comparison of colorectal cancer tissues from patients with Liver Metastasis (Exp G) and without metastasis (Ctrl G).](CAM4-5-1629-g005){#cam4738-fig-0005}

Discussion {#cam4738-sec-0017}
==========

Among numerous molecules demonstrated to play roles in CRC, lncRNAs have been the focus of increasing attention for their aberrant expression in carcinogenesis [13](#cam4738-bib-0013){ref-type="ref"}. In recent years, several lncRNAs have been found to be associated with metastasis of CRC. A previous study indicates that the role of the HOTAIR in CRC progression is associated with the acquisition of stemness, with the potential mechanism of gene silencing by binding to PRC2 and LSD1 [14](#cam4738-bib-0014){ref-type="ref"}, [15](#cam4738-bib-0015){ref-type="ref"}. The expression of metastasis‐associated lung adenocarcinoma transcript 1 (MALAT1) was found to be associated with CRC metastasis [12](#cam4738-bib-0012){ref-type="ref"}, and the down‐regulation of MALAT1 by resveratrol could decrease the nuclear localization of *β*‐catenin and attenuate Wnt/*β*‐catenin signaling, thereby inhibiting CRC invasion and metastasis [16](#cam4738-bib-0016){ref-type="ref"}. CRC‐associated transcript 2 (CCAT2) was reported to be highly overexpressed in microsatellite‐stable CRC, and to promote tumor growth and metastasis by regulating Myc and Wnt [17](#cam4738-bib-0017){ref-type="ref"}. Except for the above mentioned lncRNAs which promoted the metastasis of CRC, LOC285194, and uc.388 were shown to be a potential inhibitor and the signal pathway should be further characterized [18](#cam4738-bib-0018){ref-type="ref"}, [19](#cam4738-bib-0019){ref-type="ref"}. Nevertheless, most lncRNAs expected to be prognostic or predictive in cancer patients have failed to perform these functions when tested in vivo [12](#cam4738-bib-0012){ref-type="ref"}. As only a few lncRNAs have been well characterized [12](#cam4738-bib-0012){ref-type="ref"}, our approach provides a shortcut to identify novel targets among the many as yet uncharacterized lncRNAs. Indeed, the 2636 significantly differentially expressed (f ≥ 2.0‐fold change) lncRNAs in Exp G contain abundant information worthy of further study.

In previous studies, the abnormal expression of lncRNAs determined in CRC tissue samples was interpreted as indicative of their functional role in the underlying biological process [15](#cam4738-bib-0015){ref-type="ref"}, [20](#cam4738-bib-0020){ref-type="ref"}, [21](#cam4738-bib-0021){ref-type="ref"}. Our microarray results similarly showed the differential expression of numerous lncRNAs and mRNAs in Exp G vs. Ctrl G. GO analysis provides a discrete list of terms to describe the characteristics of gene products as well as functional annotation data from GO consortium members. In our GO analysis, the mRNAs were assigned with respect to the biological process, cellular component and molecular function associated with the most highly correlated coding genes [13](#cam4738-bib-0013){ref-type="ref"}. Unlike in previous studies [13](#cam4738-bib-0013){ref-type="ref"}, [22](#cam4738-bib-0022){ref-type="ref"}, the up‐ and down‐regulated mRNAs in this investigation were analyzed separately in both the GO and pathway analyses. This allowed the detection of obvious differences between the up‐and down‐regulated mRNAs. Using this approach, we tentatively identified several novel factors that may play important roles in the liver metastasis of CRC. In previous studies, MAPK signaling and KITLG, both of which participate in the circadian entrainment pathway, identified in association with the up‐regulated mRNAs, and the cytokine--cytokine receptor interactions, determined for down‐regulated mRNAs, were shown to be associated with the development of CRC cells [23](#cam4738-bib-0023){ref-type="ref"}, [24](#cam4738-bib-0024){ref-type="ref"}. Although lncRNAs exert diverse effects on the regulation of coding gene expression [25](#cam4738-bib-0025){ref-type="ref"}, [26](#cam4738-bib-0026){ref-type="ref"}, the exact mechanism remain to be identified.

Since the primary function of lncRNAs is the epigenetic regulation of protein‐coding genes [26](#cam4738-bib-0026){ref-type="ref"}, [27](#cam4738-bib-0027){ref-type="ref"}, detecting the expression of the target coding gene is an effective way to reveal the putative functions of lncRNAs [13](#cam4738-bib-0013){ref-type="ref"}. Therefore, as part of our study of lncRNAs, we also analyzed the mRNAs isolated from the two groups. Ten mRNAs had a high normalized intensity and high fold change, but after qRT‐PCR verification, only one (NM_000904, NQO2) was conformed to be significantly expressed.

The human NQO2 gene, located on chromosome 6p25.2, comprises seven exons (the first is noncoding) spanning 19.8 kb. NQO2 encodes a protein of 231 amino acid sand contains 254 single‐nucleotide polymorphisms within 10 kb of the 5′‐end of the first exon and 2 kb of the 3′‐end of the last exon [28](#cam4738-bib-0028){ref-type="ref"}. The traditional function of NQO2 was assigned as a phase II detoxification enzyme to protect cells against free radicals and toxic oxygen metabolites [28](#cam4738-bib-0028){ref-type="ref"}. The role of NQO2 as a tumor suppressor was raised from the studies demonstrated that NQO2 involves in the control of 20S proteasome‐mediated degradation of p53/p63 and regulates the stability of proteins [29](#cam4738-bib-0029){ref-type="ref"}, [30](#cam4738-bib-0030){ref-type="ref"}, [31](#cam4738-bib-0031){ref-type="ref"}. Furthermore, NQO2 was reported to regulate the stability of cyclin D1 in CWR22Rv1 prostate cancer cells by AKT/GSK‐3*β* signal pathway [32](#cam4738-bib-0032){ref-type="ref"}. In addition, NQO2 polymorphism was strongly associated with esophageal cancer [33](#cam4738-bib-0033){ref-type="ref"} and the lymph node metastasis of papillary thyroid microcarcinoma [34](#cam4738-bib-0034){ref-type="ref"}. NQO2 was mostly shown to be a negative modifier of carcinogenesis in breast cancer [35](#cam4738-bib-0035){ref-type="ref"}, [36](#cam4738-bib-0036){ref-type="ref"}, [37](#cam4738-bib-0037){ref-type="ref"}, skin neoplasms [38](#cam4738-bib-0038){ref-type="ref"}, [39](#cam4738-bib-0039){ref-type="ref"} prostate cancer [32](#cam4738-bib-0032){ref-type="ref"}, [40](#cam4738-bib-0040){ref-type="ref"}, radiation‐induced B‐cell lymphomas [41](#cam4738-bib-0041){ref-type="ref"} and melanoma [42](#cam4738-bib-0042){ref-type="ref"} while only one study suggested it to be a susceptibility gene for breast carcinogenesis [43](#cam4738-bib-0043){ref-type="ref"}. Nevertheless, there have been no direct reports on its altered expression in CRC, both carcinogenesis and metastasis. In this study, NQO2 was down‐regulated significantly in Exp G, suggesting its role in suppressing CRC metastasis. We also identified 769 significantly expressed lncRNAs associated with NQO2, which were integrated into a coding‐noncoding gene co‐expression network. Among the 10 qRT‐PCR‐verified lncRNAs, six showed the same significant tendency as those in the microarray results. However, for three other lncRNAs, the opposite tendency was determined, but the results were not statistically significant and the fold changes were relatively low. Further study of these lncRNAs based on a larger sample size is therefore needed. In a subsequent pathway, analysis aimed at associating the differentially expressed lncRNAs with their target genes, 27 gene pathways were associated with the up‐regulated lncRNAs and 51 with the down‐regulated lncRNAs.

In summary, in this work, we identified a series of differentially expressed lncRNAs in CRC patients with liver metastasis and without any metastasis. Of the potential lncRNAs predicted by bioinformatics analyses to be differentially expressed in the respective tissues, several were verified by qRT‐PCR. These differentially expressed lncRNAs provide novel targets for studies on the pathways and mechanisms of metastatic CRC and thus for the development of therapeutics for its diagnosis and chemoprevention.
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